|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 系统性药物治疗儿童银屑病的安全性显示文摘银屑病是一种常见的慢性炎症性皮肤病。成年人的发病率为2%~3%,其中大约有三分之一的患者在18岁之前发病。在儿童期,该病的发病率呈线性增长。从1970年至2000年,儿童银屑病的发病率增加了一倍多。尽管对许多轻度银屑病患儿而言,局部治疗已足够,但对更多可能影响生活质量的重度或顽固性的银屑病患儿,则往往需要系统性治疗。 | bronckers imgj seyger mmb west dp lara-corrales i tollefson m tom wl hogeling m belazarian l zachariae c mahé e siegfried e philipp s szalai z vleugels ra holland k murphy r baselga e cordoro k lambert j alexopoulos a mrowietz u kievit w paller as 邓婕(编译) 张锡宝(审校) 无 | 2017 | 皮肤性病诊疗学杂志2017，24，5： | 3 |
| 2 | Recombinant humanized anti-HER-2 antibody(herceptin) enhance the activity ofpaclitaxec and doxorubicin against HER2/neu overexpressing human breast cancer xenografts 显示文摘 | BASELGA J NORTON L ALBABELL J | 1998 | Cancer Res1998，58，13： | 1 |
| 3 | Recombinant humanized antiHER2 ntibody (Herceptin) enhances the antihumor activcity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts 显示文摘 | Baselga J Norton L Albanell J | 1998 | Cancer Res1998，58，13： | 1 |
| 4 | Why the epidermal growth factor receptor?显示文摘 | Baselga J | 2002 | Oncologist2002，7，4： | 1 |
| 5 | Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors显示文摘 | Calvo E Baselga J | 2006 | J Clin Oncol2006，24，14： | 1 |
| 6 | Response of processing tomato to three different levelse of water and nitrogen application 显示文摘 | Baselga Yrisarry J J | 1993 | Acta Hort1993，335，： | 1 |
| 7 | Everolimus in postmenopausal hormone-receptor-positive advanced breast Cancer显示文摘 | Baselga J Campone M Piccart M | | 0，，06： | 1 |
| 8 | Targeting tyrosine kinases in cancer: the second wave显示文摘 | Baselga J | 2006 | Science2006，312，5777： | 1 |
| 9 | Phase H study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-Weekly Schedule 显示文摘 | Baselga J Carbonell X Castaneda-Soto NJ | 2005 | J CIin Oncol2005，23，10： | 1 |
| 10 | The EGFR as a target for anticancer therapy focus on cetuximab 显示文摘 | Baselga J | 2001 | Eur J Cancer2001，37，4： | 1 |
| 11 | Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? 显示文摘 | Arteaga CL Baselga J | 2004 | Cancer Cell2004，5，： | 1 |
| 12 | Phase II mulitcenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck显示文摘 | Baselga J Trigo JM Bourhis J | 2005 | J Clin Oncol2005，23，： | 1 |
| 13 | Phase I safety,pharmacokinetic, and pharmaeodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyroslne kinase inhibitor, in patients with five selected solid tumor types显示文摘 | BASELGA J RISCHIN D RANSON M | 2002 | J Clin Oncol2002，20，21： | 1 |
| 14 | Mechanism of action of anti-HER-2 monoclonal antibodies显示文摘 | Baselga J Albanell J | 2001 | Ann Oncol2001，12，1： | 1 |
| 15 | Novel anticancer targets:revisiting ERBB2 and discovering ERBB3显示文摘 | Baselga J Swain SM | 2009 | Nat Rev Cancer2009，9，7： | 1 |
| 16 | Sorafenib in combination with capecitabine : an oral regimen for patients with HER-2 negative locally advanced or metastatic breast cancer 显示文摘 | Baselga J Segalla JG Roche H | 2012 | J Clin Oncol2012，30，13： | 1 |
| 17 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):a randomised,open-label,multicentre,phase 3 trial显示文摘 | Baselga J Bradbury I Eidtmann H | | 0，，9816： | 1 |
| 18 | The EGFR as a target for anticancer therapy-focus oncetuxim-ab显示文摘 | Baselga J | | 0，，4： | 1 |
| 19 | Phase II study of weekly in travenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER2/ neu2-overexpressing metastatic breast cancer 显示文摘 | Baselga J Tripathy D Mendelsohn J | 1996 | J Clin Oncol1996，14，3： | 1 |
| 20 | New techonologies in epidermal growth factor receptor-targeted cancer therapy 显示文摘 | Baselga J | 2000 | Signal2000，1，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员